ABCL · AbCellera Biologics Inc.

The thesis

AbCellera's shares rest on one question: does ABCL635, an injectable antibody for menopausal hot flashes, keep working well beyond week 4? The 12-week and open-label extension data guided for year-end settle it. Until then the near-term read is weak. The International Menopause Society (IMS) presentation that drove the late-September run has passed without new durability figures, and the shares fell on the day.

AbCellera presented the interim Phase 1/2 results orally at the IMS 20th World Congress in Rio de Janeiro on 1 October 2026. Searches of public coverage the next day found no new durability numbers from the session. The adjusted close fell to $13.91 on 1 October 2026, from $14.59 on 30 September 2026. That left the shares 6.1% below the $14.82 52-week high.

The narrative is maturing. The week-4 result has been public since 10 August 2026. Goldman Sachs and JPMorgan both took their positions in the last week of September. The 1 October 2026 presentation was the last scheduled ABCL635 event before the year-end data. Within the precision-biotech group the story is different: that cluster turned back to accelerating on 1 October 2026 after two weeks rated saturated. That helps the shares only while the group holds up. It does not supply ABCL635 news.

Bullish and bearish views on AbCellera Biologics Inc.

The bull case on AbCellera Biologics Inc. (ABCL), in brief: The controlled week-4 effect is large. The bear case: The data still cover four weeks.

Bull case

• The controlled week-4 effect is large. AbCellera's 10 August 2026 release covered the 92-patient Phase 2. A single 600 mg dose cut moderate-to-severe hot flashes by 8.8 events per day at week 4, against 3.5 on placebo. Mean frequency fell 83% on drug and 33% on placebo. Both primary endpoints were met.
• Pharmacology supports monthly dosing. AbCellera's Q1 2026 results release in May reported interim Phase 1 data. They showed an estimated half-life of about 24 days and no serious adverse events or liver toxicity. On that basis the company positions ABCL635 as a potential once-monthly subcutaneous dose, against daily oral pills.
• Most sell-side targets sit above the market. Truist's target is $30 (11 August 2026), JonesResearch's is $25 and JPMorgan's is $17 (29 September 2026). Truist and JonesResearch cite peak sales of about $2.5 billion. JPMorgan surveyed 13 physicians who treat about 4,100 menopausal patients and found an average expected adoption of 38%.
• Cash funds the path to Phase 3. The Q2 release on 5 August 2026 reported more than $565 million in cash and marketable securities. Management told the Cantor conference on 9 September 2026 that it plans to start Phase 3 in the second half of 2027.

Bear case

• The data still cover four weeks. The case against the daily oral NK3 antagonists Veozah (fezolinetant, Astellas) and Lynkuet (elinzanetant, Bayer) rests on infrequent dosing. Only the 12-week and extension data can show whether the effect holds. Management guided those for year-end at the 9 September 2026 Cantor conference.
• News flow goes quiet until year-end. With the 1 October 2026 presentation done, the next confirmed company event is the Q3 report on 9 November 2026. AbCellera announced that date on 1 October 2026. No ABCL635 slot at The Menopause Society meeting (20 October to 24 October 2026) had been announced as of 3 September 2026.
• Goldman's target sits below the market. Goldman Sachs reinstated coverage at Neutral with a $13 target on 24 September 2026. That is below the $13.91 close on 1 October 2026.
• Core revenue is shrinking. Q2 2026 revenue was $4.1 million, against $17.1 million in Q2 2025, and the quarter's net loss was $55.4 million (company release, 5 August 2026). That leaves the equity valued almost entirely on one clinical asset.

Price setup

The shares closed at $13.91 on 1 October 2026 on the split- and dividend-adjusted daily series. That is 6.1% below the $14.82 52-week high, with a three-month gain of 76.7%. The 14-day relative strength index (RSI) eased to 76.3, from 87.6 on 30 September 2026. It is still in overbought territory.

The crowding signs can be measured. The shares rose 76.7% in three months. Two major banks initiated or reinstated coverage within five days of each other. No insider-transaction data were reviewed for this note.

The reference levels are these. The $14.82 52-week high is overhead. Goldman's $13 target and the $12.63 close of 18 September 2026 sit below. The $12.63 close marks where the shares stood before the sell-side initiations. Further down, the $9.75 offering price anchors the post-data range.

Catalysts, next 30 days

• 20 October to 24 October 2026: The Menopause Society Annual Meeting, San Diego. This is a possible second venue for ABCL635 data. No AbCellera presentation had been announced as of 3 September 2026.
• 9 November 2026 (after the 30-day window): Q3 2026 results, with a call at 5:00 p.m. Eastern. The report gives the first cash figure after the offering and the trend in discovery revenue. It may also give a firm date for the 12-week data.
• ~2026-Q4 (est.): ABCL635 12-week and open-label extension data, and ABCL575 Phase 1 top-line results in atopic dermatitis. The 12-week dataset is the durability test the case turns on.

What would change the view

The clinical case breaks if the 12-week or extension data show the single-dose effect fading. A placebo-adjusted cut in hot-flash frequency well below the week-4 gap of 5.3 events per day would show that. A safety-driven pause of ABCL635 would also break it, as would a Phase 3 design that needs dosing more often than monthly. On price, a weekly close below $12.63 would erase the advance that followed the September initiations.

The read would strengthen if AbCellera put a firm date on the 12-week data and the shares then made a weekly close above the $14.82 52-week high. Durability data that hold the week-4 effect would move the case from a single-timepoint result to a dosing advantage.

What it trades with

ABCL trades mostly on its own clinical news. It also moves with the precision-biotech group, which includes IOVA, AGEN, SRZN, EPRX, SMMT, PGEN and KOD. That group was rated saturated on 20 September 2026 and turned back to accelerating on 1 October 2026. A cooling group would remove support while ABCL635 news is thin. Competitor news matters too: label, safety or pricing updates for Astellas's Veozah or Bayer's Lynkuet change how the market judges an injectable NK3 option.